Best-in-class compound identified via best-in-class profiling method. Maybe not a coincidence.
Congratulations to Repare on the progress shown for the ATR inhibitor camonsertib (RP-3500) in the clinic. Selectivity of RP-3500 was determined on KiNativ (https://t.co/nbwOuC0cS4)
RT @MCT_AACR: Targeting ATR is being investigated as an approach to treating the many cancers that have DNA repair pathway defects. RP-3500…
Targeting ATR is being investigated as an approach to treating the many cancers that have DNA repair pathway defects. RP-3500 is novel ATR inhibitor shown to be effective at reducing tumor growth in several preclinical models of cancer. https://t.co/UaSAj3
RT @MCT_AACR: Roulston et al present a preclinical rational to support ongoing clinical investigation of the novel ATR inhibitor RP-3500 as…
Roulston et al present a preclinical rational to support ongoing clinical investigation of the novel ATR inhibitor RP-3500 as #monotherapy and in combination with PARP inhibitors as a means of maximizing clinical benefit. https://t.co/fsby93eulF https://t.
MCT First Disclosure: RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors. https://t.co/m2Md1vmOAt https://t.co/ZGBXiVEln0
RT @RepareRx: We’re pleased to announce that our recent pharmacology manuscript detailing our novel, potent and selective ATR inhibitor, RP…
RT @RepareRx: We’re pleased to announce that our recent pharmacology manuscript detailing our novel, potent and selective ATR inhibitor, RP…
RT @nanudasmd: Exciting to see the ATRi plus PARPi story continue to evolve, with exploration of intermittent dosing schedules preclinicall…
RT @RepareRx: We’re pleased to announce that our recent pharmacology manuscript detailing our novel, potent and selective ATR inhibitor, RP…
RT @RepareRx: We’re pleased to announce that our recent pharmacology manuscript detailing our novel, potent and selective ATR inhibitor, RP…
RP-3500: A Novel, Potent and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors https://t.co/vvmCMeVCXp
RT @RepareRx: We’re pleased to announce that our recent pharmacology manuscript detailing our novel, potent and selective ATR inhibitor, RP…
RT @RepareRx: We’re pleased to announce that our recent pharmacology manuscript detailing our novel, potent and selective ATR inhibitor, RP…
RT @RepareRx: We’re pleased to announce that our recent pharmacology manuscript detailing our novel, potent and selective ATR inhibitor, RP…
RT @RepareRx: We’re pleased to announce that our recent pharmacology manuscript detailing our novel, potent and selective ATR inhibitor, RP…
RT @nanudasmd: Exciting to see the ATRi plus PARPi story continue to evolve, with exploration of intermittent dosing schedules preclinicall…
RT @RepareRx: We’re pleased to announce that our recent pharmacology manuscript detailing our novel, potent and selective ATR inhibitor, RP…
Exciting to see the ATRi plus PARPi story continue to evolve, with exploration of intermittent dosing schedules preclinically. Hopefully, will mitigate some of the overlapping heme tox which has been observed clinically @MCT_AACR @AACR @VUMC_Cancer https
RT @RepareRx: We’re pleased to announce that our recent pharmacology manuscript detailing our novel, potent and selective ATR inhibitor, RP…
We’re pleased to announce that our recent pharmacology manuscript detailing our novel, potent and selective ATR inhibitor, RP-3500, has been published in @MCT_AACR. Read the publication here: https://t.co/k4dntQWdir